SEC Form 4 · accession 0001209191-18-030207
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ian F Smith
Officer — EVP, COO
Period of report
May 11, 2018
Accepted (ET)
May 15, 2018 · 4:21 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 11, 2018 | M | 2,155 | $91.05 | A | 48,854 | D | |
| Common Stock | May 11, 2018 | M | 1,941 | $86.52 | A | 50,795 | D | |
| Common Stock | May 11, 2018 | S | 4,096 | $155.00 | D | 46,699 | D | |
| Common Stock | holding | — | — | — | 5,306 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $91.05 | May 11, 2018 | M | 2,155 | D | — | Feb 1, 2026 | Common Stock | 2,155 | 15,086 | D |
| Stock Option (Right to Buy)F3 | $86.52 | May 11, 2018 | M | 1,941 | D | — | Feb 2, 2027 | Common Stock | 1,941 | 21,358 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1.
- F2The option vests in 16 quarterly installments from 2/2/2016.
- F3The option vests in 16 quarterly installments from 2/3/2017.